Protecting livestock and livelihoods with a dual-action vaccine

09 July 2025

Cattle ticks are notorious for spreading tick fever, a potentially fatal disease that threatens the health of beef and dairy cows in Australia and around the world. The only currently available vaccine is expensive to produce, hard to deploy, and does not prevent the infected tick from transmitting the disease to other animals. Dr Vignesh Ambothi Rathinasamy and Adjunct Professor Brian Cooke from the Australian Institute of Tropical Health and Medicine (AITHM) are developing an alternative vaccine that aims to be more affordable, more effective and easier to deploy.

Cattle ticks transmit tick fever, also known as bovine babesiosis, in tropical and subtropical regions with high humidity, such as South and South East Asia, Sub-Saharan Africa, Central and South America, and most of Northern Australia.

“Tick fever can result in high mortality in cattle, but we don't actually know what the true economic impact is on the beef and dairy industry — it’s potentially a lot worse than commonly known,” Professor Cooke said. “It's very hard to get this data. We are now working with collaborators in the United States, Egypt and Türkiye to assess the global economic impact of cattle tick fever.”

In Australia, a vaccine is available from the Tick Fever Centre in Brisbane for about six dollars per dose. The vaccines need to be stored and transported at 2–8°C and must be used within four days of manufacture. “If you are a beef farmer in the Northern Territory and you're running twenty or thirty thousand head of cattle, the cost adds up and will have an impact on the bottom line of the business,” Professor Cooke said.

Additionally, in some regions in Asia and Sub-Saharan Africa, subsistence farmers might only own one or two cows and often cannot afford the vaccine. Dr Rathinasamy, who grew up in South India, understands the challenges firsthand. “A family’s livelihood may rely on that one animal,” he said. “They might not be able to afford the vaccine, nor do they own a fridge to store it.”

This is why Dr Rathinasamy and Professor Cooke are approaching the development of their tick vaccine from two key perspectives. “Our goal is to have not only a vaccine that protects the animals against disease, but that also cures the tick so it cannot transmit bovine babesiosis to other cattle,” Professor Cooke said. “This is something that has never been done before.”

The team have already conducted two successful large-animal trials with potential vaccine candidates in Queensland and in the United States. “One of the vaccines that we have co-developed with Dr Carlos Suarez from the United States Department of Agriculture has completely blocked the parasite circulation in the ticks,” Dr Rathinasamy said.

“We are very excited about that, as it provides 100% protection. This could be turned into an effective vaccine as soon as we can find some investors to fund the venture.”

The researchers are also seeing promising results in blocking the parasites in the cattle itself, but further work is needed before the vaccine candidate is market-ready. “It's showing strong signs towards protection, but we still need to fine-tune it to make it more effective,” Dr Rathinasamy said.

Professor Cooke and Dr Rathinasamy are currently being supported by the Australian Research Council (ARC), which is funding their research into loopholes in the parasite’s lifecycle that might be used as potential targets for new vaccines.

Additionally, funding from the Bill and Melinda Gates Foundation and the Canadian International Development Research Centre (IDRC) expired in late 2024, leaving the researchers seeking new donors and investors.

Their current research also includes a spin-off project that aims to reduce methane emissions produced by cattle — a promising extension of their current research.